Indonesia

| High TB burden | High HIV burden | High MDR-TB burden |

Population 2012 Estimates of TB burden * 2012 Mortality (excludes HIV+TB) Mortality (HIV+TB only) Prevalence (includes HIV+TB) Incidence (includes HIV+TB) Incidence (HIV+TB only) Case detection, all forms (%) TB case notifications 2012 New cases Smear-positive Smear-negative Smear-unknown / not done Extrapulmonary Other Total new Other (history unknown) Total new and relapse Number (thousands) 67 (30120) 2.1 (1.83) 730 (3501 200) 460 (380540) 7.5 (5.69.7) 72 (6187) 247 million Rate (per 100 000 population) 27 (1248) 0.86 (0.741.2) 297 (144506) 185 (153220) 3.1 (2.33.9)

Tuberculosis profile
*** (Rate per 100 000 population per year) 100 50 0 1990
___

1994

1998

2002

2006

2010

Mortality (excludes HIV+TB)

(%) Retreatment cases 202 319 (63) Relapse 104 866 (32) Treatment after failure Treatment after default 15 697 (5) Other 322 882 Total retreatment

5 942 467 954 1 179 8 542

(%) (70) (5) (11) (14)

(Rate per 100 000 population) 800 400 0 1990

___

1994

1998

2002

2006

2010

Prevalence

328 824

Total cases notified Smear-negative/ unknown/ not done 1.3 22 956

331 424

(Rate per 100 000 population per year) 300 200 100 0 1990 1994 1998 2002 2006 2010

New cases M:F ratio Age < 15

Smear-positive 1.5 1 703

Extrapulmonary 0.9 2 684 2012 2.3 0.9 0.1 Yes, in country

Laboratories Smear (per 100 000 population) Culture (per 5 million population) Drug susceptibility testing (per 5 million population) Is second-line drug susceptibility testing available? Treatment success rate 2011 (%) New smear-positive and/or culture-positive New smear-negative/extrapulmonary Retreatment

__
___

Notifications ___ Incidence Incidence (HIV+TB only)

Treatment success rate (%) 90

90 85 71

Is rifampicin used throughout treatment for new patients? Number 2 676 754 133 221 22 677

70 Yes (%) (<1) (28) (18) (29) 50 30 1995 1997 1999 2001 2003 2005 2007 2009

TB/HIV 2012 TB patients with known HIV status HIV-positive TB patients HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) HIV-positive TB patients on antiretroviral therapy (ART) HIV-positive people screened for TB HIV-positive people provided with IPT Estimates of MDR-TB burden 2012* % of TB cases with MDR-TB MDR-TB cases among notified pulmonary TB cases Reported cases of MDR-TB 2012 Cases tested for MDR-TB Laboratory-confirmed MDR-TB cases Patients started on MDR-TB treatment Financing TB control National TB programme budget (US$ millions) % Funded domestically % Funded internationally % Unfunded New 1.9 (1.42.5) 5 800 (4 3007 700) New 2 (<1%) 2

__ New smear-positive and/or culture-positive __New smear-negative/extrapulmonary __

Retreatment (Number of patients) 3000 2000

Retreatment 12 (8.117) 1 000 (6901 500) Retreatment 821 (10%) 425 Total 824 428 426 2013 119 14% 35% 51%

1000 0 2003 2005 2007 2009 2011

__ HIV-positive TB patients __on CPT __on ART

Total budget (US$ millions) 120 80 40 0 2009 2010 2011 2012 2013

__ __

Funded domestically Unfunded

__

Funded internationally

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. * Ranges represent uncertainty intervals Generated: 2013-12-07

Data: www.who.int/tb/data